Efficacy of aprepitant in preventing nausea and vomiting due to high-dose melphalan-based conditioning for allogeneic hematopoietic stem cell transplantation

Masatoshi Sakurai, Takehiko Mori, Jun Kato, Yuya Koda, Taku Kikuchi, Sumiko Kohashi, Masuho Saburi, Takaaki Toyama, Yoshinobu Aisa, Tomonori Nakazato, Noriko Beppu, Soichiro Tsuda, Naoyuki Shigematsu, Shinichiro Okamoto

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

High-dose melphalan has been gaining recognition as a highly emetogenic agent used in hematopoietic stem cell transplantation (HSCT). The aim of this retrospective study was to elucidate the efficacy of aprepitant in preventing high-dose melphalan-induced emesis. Sixty patients who received melphalan (70 mg/m2/day, 2 days) and fludarabine (125 mg/m2/day, 5 days) as conditioning for allogeneic HSCT for hematological malignancies, and who received ondansetron and methylprednisolone as an antiemetic prophylaxis, were eligible. Twenty of these 60 patients also received aprepitant for 5 days (aprepitant group); the remaining 40 patients served as a control. The rates of complete response (CR), defined as no emesis without rescue medications, and complete protection (CP), defined as no emesis with or without rescue medications, were assessed between the two groups. The observation period was 12 days from the first day of melphalan administration. The CR and CP rates were significantly higher in the aprepitant group than in the control group during the observation period (35 % versus 10 %, P < 0.05; 85 % versus 33 %, P < 0.001; respectively). These results suggest that aprepitant in combination with ondansetron and steroid effectively ameliorates nausea and vomiting caused by the high-dose melphalan-based conditioning for allogeneic HSCT.

Original languageEnglish
Pages (from-to)457-462
Number of pages6
JournalInternational Journal of Hematology
Volume99
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

aprepitant
Melphalan
Hematopoietic Stem Cell Transplantation
Nausea
Vomiting
Ondansetron
Observation
Antiemetics
Methylprednisolone
Hematologic Neoplasms
Retrospective Studies
Steroids
Control Groups

Keywords

  • Allogeneic hematopoietic stem cell transplantation
  • Aprepitant
  • High-dose melphalan
  • Nausea

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Efficacy of aprepitant in preventing nausea and vomiting due to high-dose melphalan-based conditioning for allogeneic hematopoietic stem cell transplantation. / Sakurai, Masatoshi; Mori, Takehiko; Kato, Jun; Koda, Yuya; Kikuchi, Taku; Kohashi, Sumiko; Saburi, Masuho; Toyama, Takaaki; Aisa, Yoshinobu; Nakazato, Tomonori; Beppu, Noriko; Tsuda, Soichiro; Shigematsu, Naoyuki; Okamoto, Shinichiro.

In: International Journal of Hematology, Vol. 99, No. 4, 2014, p. 457-462.

Research output: Contribution to journalArticle

@article{3b675fac0f664b9884cd98e1036bf020,
title = "Efficacy of aprepitant in preventing nausea and vomiting due to high-dose melphalan-based conditioning for allogeneic hematopoietic stem cell transplantation",
abstract = "High-dose melphalan has been gaining recognition as a highly emetogenic agent used in hematopoietic stem cell transplantation (HSCT). The aim of this retrospective study was to elucidate the efficacy of aprepitant in preventing high-dose melphalan-induced emesis. Sixty patients who received melphalan (70 mg/m2/day, 2 days) and fludarabine (125 mg/m2/day, 5 days) as conditioning for allogeneic HSCT for hematological malignancies, and who received ondansetron and methylprednisolone as an antiemetic prophylaxis, were eligible. Twenty of these 60 patients also received aprepitant for 5 days (aprepitant group); the remaining 40 patients served as a control. The rates of complete response (CR), defined as no emesis without rescue medications, and complete protection (CP), defined as no emesis with or without rescue medications, were assessed between the two groups. The observation period was 12 days from the first day of melphalan administration. The CR and CP rates were significantly higher in the aprepitant group than in the control group during the observation period (35 {\%} versus 10 {\%}, P < 0.05; 85 {\%} versus 33 {\%}, P < 0.001; respectively). These results suggest that aprepitant in combination with ondansetron and steroid effectively ameliorates nausea and vomiting caused by the high-dose melphalan-based conditioning for allogeneic HSCT.",
keywords = "Allogeneic hematopoietic stem cell transplantation, Aprepitant, High-dose melphalan, Nausea",
author = "Masatoshi Sakurai and Takehiko Mori and Jun Kato and Yuya Koda and Taku Kikuchi and Sumiko Kohashi and Masuho Saburi and Takaaki Toyama and Yoshinobu Aisa and Tomonori Nakazato and Noriko Beppu and Soichiro Tsuda and Naoyuki Shigematsu and Shinichiro Okamoto",
year = "2014",
doi = "10.1007/s12185-014-1538-6",
language = "English",
volume = "99",
pages = "457--462",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Efficacy of aprepitant in preventing nausea and vomiting due to high-dose melphalan-based conditioning for allogeneic hematopoietic stem cell transplantation

AU - Sakurai, Masatoshi

AU - Mori, Takehiko

AU - Kato, Jun

AU - Koda, Yuya

AU - Kikuchi, Taku

AU - Kohashi, Sumiko

AU - Saburi, Masuho

AU - Toyama, Takaaki

AU - Aisa, Yoshinobu

AU - Nakazato, Tomonori

AU - Beppu, Noriko

AU - Tsuda, Soichiro

AU - Shigematsu, Naoyuki

AU - Okamoto, Shinichiro

PY - 2014

Y1 - 2014

N2 - High-dose melphalan has been gaining recognition as a highly emetogenic agent used in hematopoietic stem cell transplantation (HSCT). The aim of this retrospective study was to elucidate the efficacy of aprepitant in preventing high-dose melphalan-induced emesis. Sixty patients who received melphalan (70 mg/m2/day, 2 days) and fludarabine (125 mg/m2/day, 5 days) as conditioning for allogeneic HSCT for hematological malignancies, and who received ondansetron and methylprednisolone as an antiemetic prophylaxis, were eligible. Twenty of these 60 patients also received aprepitant for 5 days (aprepitant group); the remaining 40 patients served as a control. The rates of complete response (CR), defined as no emesis without rescue medications, and complete protection (CP), defined as no emesis with or without rescue medications, were assessed between the two groups. The observation period was 12 days from the first day of melphalan administration. The CR and CP rates were significantly higher in the aprepitant group than in the control group during the observation period (35 % versus 10 %, P < 0.05; 85 % versus 33 %, P < 0.001; respectively). These results suggest that aprepitant in combination with ondansetron and steroid effectively ameliorates nausea and vomiting caused by the high-dose melphalan-based conditioning for allogeneic HSCT.

AB - High-dose melphalan has been gaining recognition as a highly emetogenic agent used in hematopoietic stem cell transplantation (HSCT). The aim of this retrospective study was to elucidate the efficacy of aprepitant in preventing high-dose melphalan-induced emesis. Sixty patients who received melphalan (70 mg/m2/day, 2 days) and fludarabine (125 mg/m2/day, 5 days) as conditioning for allogeneic HSCT for hematological malignancies, and who received ondansetron and methylprednisolone as an antiemetic prophylaxis, were eligible. Twenty of these 60 patients also received aprepitant for 5 days (aprepitant group); the remaining 40 patients served as a control. The rates of complete response (CR), defined as no emesis without rescue medications, and complete protection (CP), defined as no emesis with or without rescue medications, were assessed between the two groups. The observation period was 12 days from the first day of melphalan administration. The CR and CP rates were significantly higher in the aprepitant group than in the control group during the observation period (35 % versus 10 %, P < 0.05; 85 % versus 33 %, P < 0.001; respectively). These results suggest that aprepitant in combination with ondansetron and steroid effectively ameliorates nausea and vomiting caused by the high-dose melphalan-based conditioning for allogeneic HSCT.

KW - Allogeneic hematopoietic stem cell transplantation

KW - Aprepitant

KW - High-dose melphalan

KW - Nausea

UR - http://www.scopus.com/inward/record.url?scp=84899630087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899630087&partnerID=8YFLogxK

U2 - 10.1007/s12185-014-1538-6

DO - 10.1007/s12185-014-1538-6

M3 - Article

VL - 99

SP - 457

EP - 462

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 4

ER -